Millendo Therapeutics Receives $62,000,000 Series B Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=6794ee49-4c1d-40fe-898b-b602349ea9ff - Date
1/4/2016 - Company Name
Millendo Therapeutics - Mailing Address
301 N. Main St. Ann Arbor, MI 48104 USA - Company Description
Millendo Therapeutics is focused on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. Our product candidates seek to improve the quality of life for patients with orphan and specialty diseases with limited or no approved treatment options. - Website
http://www.millendo.com - Transaction Type
Venture Equity - Transaction Amount
$62,000,000 - Transaction Round
Series B - Proceeds Purposes
This acquisition of MLE4901 combined with the new funding and our current programs around ATR-101 puts us on a new trajectory to build a specialty pharmaceutical company focused on multiple disease-modifying treatments for endocrine disorders caused by hormone dysregulation. - M&A Terms
- Venture Investor
New Enterprise Associates - Venture Investor
Roche Venture Fund - Venture Investor
Frazier Healthcare Partners - Venture Investor
Adams Street Partners - Venture Investor
Altitude Life Science Ventures - Venture Investor
Longwood Fund - Venture Investor
Renaissance Venture Capital Fund - Venture Investor
Osage Partners - Venture Investor
5AM Ventures - Venture Investor
University of Michigan
